ACPred

ACPred predicts anticancer peptides (ACPs) from peptide sequences using machine learning algorithms including support vector machines and random forests.

Key Features:

• Machine Learning-Based Prediction: Uses support vector machines (SVM) and random forest algorithms to classify peptides with potential anticancer activity.
• Comprehensive Peptide Feature Analysis: Incorporates multiple peptide sequence features to characterize physicochemical and structural properties associated with anticancer peptides.
• High-Accuracy Classification: Achieves an overall prediction accuracy of 95.61% evaluated using jackknife cross-validation.
• Feature Interpretation: Analyzes peptide characteristics such as hydrophobic residues, amphipathic α-helical structures, and β-sheet disulfide bridges associated with anticancer activity.

Scientific Applications:

• Anticancer Peptide Discovery: Identifies candidate peptides with potential anticancer activity for therapeutic development.
• Peptide-Based Drug Development: Supports screening of peptide libraries to discover bioactive peptides for oncology research.
• Structure–Function Analysis of Bioactive Peptides: Investigates sequence and structural properties associated with cytotoxic activity against cancer cells.

Methodology:

ACPred extracts peptide sequence features, trains support vector machine and random forest classifiers on labeled anticancer and non-anticancer peptides, and evaluates predictive performance using jackknife cross-validation.